



Resolution n°2-2024-e

Cost Extension for the Project “Integrating PrEP into Comprehensive Services for Adolescent Girls and Young Women”

Recalling Unitaid Board Resolution R21-2017-e in which the Board authorized the Executive Director to commit up to US\$ 10,662,674 for the project entitled “Integrating PrEP into Comprehensive Services for Adolescent Girls and Young Women” (the “Project”), to be implemented by Wits Health Consortium (Pty) Ltd on behalf of Wits Reproductive Health and HIV Institute (“Wits RHI”) for a 3-year period;

Noting that in 2020 and 2021, the Secretariat approved two no-cost extensions to the duration of funding for the Project of 9 and 3 months respectively, together ending on 31 December 2021;

Recalling Resolution R27-2021-e, in which the Board approved additional funding of up to US\$ 9,861,380 for the expansion of PrEP options within the Project activities, and extended the duration of funding for the Project by 3 years to 31 December 2024;

Noting that the Medicines Patent Pool (MPP) has this year awarded sublicenses to three generic manufacturers to develop generic long acting cabotegravir (“LA-CAB”); and acknowledging the additional opportunities in this context to accelerate the availability and affordability of quality-assured, generic LA-CAB through the expansion of the Project to support market shaping interventions; and

Taking into account the assessment by the PRC and the Secretariat’s recommendations with respect to the Project extension proposal submitted by Wits RHI, the Board authorizes the Executive Director, subject to the availability of funds, to commit additional funding of up to US\$ 15.000.000 for the Project and to extend the duration of funding for the Project up to 31 December 2026, subject to the signature of a formal amendment to the legal agreement for the Project.

The additional funding and extension to the Project shall not apply to the original outputs 1-3 and is conditional upon signature of a formal amendment to the grant agreement for the Project.

A handwritten signature in blue ink that reads "Marisol Touraine".

Marisol Touraine
Chair of the Executive Board

Date: 8 January 2024